LeMaitre Vascular
S&P 600
$80.59
+2.27%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| Stryker Corporation | $ 275.56 | $105.70B | 28.59 | 4.41 | 27.67 | 12.18 | 1.29 | Above FV |
| Tandem Diabetes Care | $ 17.11 | $1.19B | -1,711.00 | 9.13 | -157.00 | -20.54 | 0.00 | — |
| Abbott Laboratories | $ 101.95 | $176.41B | 32.99 | 3.45 | 12.53 | 8.57 | 2.40 | Above FV |
| Intuitive Surgical | $ 369.15 | $132.26B | 42.38 | 7.19 | 15.72 | 15.61 | 0.00 | Above FV |
| Medtronic | $ 90.96 | $116.35B | 22.40 | 2.32 | 9.56 | 7.92 | 3.11 | Above FV |
| Boston Scientific | $ 42.98 | $62.29B | 17.40 | 2.49 | 11.60 | 9.08 | 0.00 | Above FV |
| Becton Dickinson | $ 177.85 | $48.44B | 30.77 | 1.98 | 6.87 | 6.08 | 2.38 | Above FV |
| Edwards Lifesciences | $ 84.37 | $48.63B | 50.22 | 4.58 | 10.11 | 10.49 | 0.00 | Above FV |
| Idexx Laboratories | $ 504.70 | $39.76B | 35.47 | 24.69 | 65.70 | 59.30 | 0.00 | Above FV |
| Dexcom | $ 83.03 | $31.33B | 32.82 | 11.95 | 31.90 | 21.14 | 0.00 | Above FV |
| ResMed | $ 218.27 | $31.49B | 20.93 | 4.78 | 23.13 | 24.92 | 1.09 | Above FV |
| GE HealthCare | $ 63.93 | $28.88B | 14.73 | 2.63 | 19.54 | 9.86 | 0.22 | Above FV |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.